|
|
|
|
|
15.07.26 - 22:36
|
Rakovina Therapeutics Announces $1.5 Million Private Placement (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, today announces a non-brokered private placement offering (the “Offering”) of up to $1.5 million....
|
|
|
|
|
|
|
|
|
30.04.26 - 23:12
|
Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7J0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a corporate update....
|
|
|
|
|
|
|
12.03.26 - 20:30
|
Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that the TSXV has granted the Company a 30-day extension with respect to its non-brokered private placement financing (the “Offering”), previously announced on January 27, 2026 and February 20, 2026. The Offering is now expected to close on or before April 9, 2026, or other such date or dates as determined by the Company and acceptable to the TSXV....
|
|
|
06.03.26 - 02:09
|
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce closing of its previously announced non-brokered private placement of convertible debenture units (“Debenture Units”) for aggregate gross proceeds of $1,000,000 (the “Debenture Private Placement”). The Company also announces that it has entered into the previously announced debt settlement agreements with holders of the 12.0% unsecured convertible debentures of the Company (the “Existing Debentures”) to settle an aggregate outstanding debt of $1,587,130.59 (the “Settled Amount”), comprised of a principal amount of $1,454,000.00 and accrued interest of $133,130.59 as at March 5, 2026. In full satisfaction and settlement of the Settled Amount, the Company has agreed to issue (i) an aggregate of approximately 3,265,58...
|
|
|
23.02.26 - 09:51
|
XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 3 (XETRA)
|
|
|
US11259P1093
GB00BJQTGV64
PLIPOSA00010
PLICI0000010
US72815G1085
CA92537Y1043
SE0016802797
CA7480331072
SE0016843809
SE0015797873
CA89602T1012
PLGDVIS00018
AU0000157455
CA75103L3092
PLDGNST00012
CA02074J5017
US68235C2061
KYG2993S1066
JP3141600001
PLSFD0000013
JP3396000006
US82322J1079
IT0005499949
US8122152007
PLIMGPW00013
SE0004899474
SE0009920994
US15102K1007
CA3933801001
US7004021009
JP3966660007
GB00BVZNY531
GB00BNG59574
BE0974380124
AU0000134694
JP3480600000
JP3187000009
CY0103562118
PLBLKPC00014
CA6488301079
CNE100004JD2
IT0005442154
AU0000141533
US4652701065
GB00BMC2XX17
PLROCCA00013
SE0005676103
AU0000058943
GB00BF044593
AU0000129496
CNE100003FC4
PLSMFBC00016
CA75585H2063
MU0461N00015
CA5791761086
JP3548660004
JP3497400006
JP3896000001
CA57778R1001
CNE100006V73
JP3335410001
CA72583H1064
JP3880800002
KYG2163K1076
US0269481091
HK0000735800
PLAIRMK00017
PLFRENT00014
PLCRBON00018
AU0000177271
DK0061411964
CA3686501071
BMG916101576...
|
|
|
|
|
|
|
|
|
|
|
|
|
17.12.25 - 10:06
|
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that senior members of the Company's executive leadership will be in San Francisco, California during the week of the annual J.P. Morgan Healthcare Conference (January 12-16, 2026) for a series of meetings with potential partners and members of the investment community.In addition, members of the Rakovina team will participate in Fierce JPM Week as part of the week's broader industry programming.“JPM week brings together a broad cross-section of global biotech and pharma leaders, and it remains one of the most efficient windows of the year for high-quality, in-person partnering discussions,” said Jeffrey Bacha, executive chairman of Rakovina. “Given the interest in AI drug development and the excitement stemming from the Company\...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
